Omnicell/$OMCL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Ticker
$OMCL
Sector
Primary listing
Employees
3,650
Headquarters
Website
Omnicell Metrics
BasicAdvanced
$1.4B
63.10
$0.49
0.88
-
Price and volume
Market cap
$1.4B
Beta
0.88
52-week high
$51.85
52-week low
$22.66
Average daily volume
394K
Financial strength
Current ratio
1.421
Quick ratio
1.084
Long term debt to equity
15.65
Total debt to equity
29.483
Interest coverage (TTM)
2.37%
Profitability
EBITDA (TTM)
67.394
Gross margin (TTM)
43.88%
Net profit margin (TTM)
2.01%
Operating margin (TTM)
1.09%
Effective tax rate (TTM)
36.13%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
0.35%
Return on equity (TTM)
1.87%
Valuation
Price to earnings (TTM)
63.1
Price to revenue (TTM)
1.257
Price to book
1.15
Price to tangible book (TTM)
4.18
Price to free cash flow (TTM)
16.206
Free cash flow yield (TTM)
6.17%
Free cash flow per share (TTM)
1.919
Growth
Revenue change (TTM)
6.39%
Earnings per share change (TTM)
-208.31%
3-year revenue growth (CAGR)
-2.95%
10-year revenue growth (CAGR)
9.52%
3-year earnings per share growth (CAGR)
-26.81%
10-year earnings per share growth (CAGR)
-5.41%
What the Analysts think about Omnicell
Analyst ratings (Buy, Hold, Sell) for Omnicell stock.
Bulls say / Bears say
Recurring revenue now represents 56% of total revenue in Q1 2025, reducing dependence on one-time device sales and improving revenue predictability. (Investing.com)
Total revenues in Q1 2025 rose 10% YoY to $270 million, and non-GAAP net income increased to $12 million (EPS $0.26), driven by strong growth in the XT Amplify program and SaaS and Expert Services. (Omnicell IR)
Management authorized a new $75 million stock repurchase program and benefited from a temporary U.S. tariff reduction on Chinese imports from 145% to 30%, reflecting confidence in free cash flow and lowering near-term cost pressures. (RTTNews)
Tariff headwinds are expected to weigh on profitability, with management forecasting a $40 million annual non-GAAP EBITDA impact from Chinese import tariffs and widening profit guidance ranges. (Ainvest)
In Q2 2025, non-GAAP EBITDA declined 4% YoY to $38 million and non-GAAP EPS fell to $0.45, indicating margin pressure despite revenue growth. (Investing.com)
Connected devices and software licenses revenue for full year 2025 is projected to grow less than 1% YoY ($625 million–$640 million vs prior year), highlighting a slowdown in equipment sales amid the XT Series replacement cycle. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Omnicell Financial Performance
Revenues and expenses
Omnicell Earnings Performance
Company profitability
Omnicell News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omnicell stock?
Omnicell (OMCL) has a market cap of $1.4B as of October 26, 2025.
What is the P/E ratio for Omnicell stock?
The price to earnings (P/E) ratio for Omnicell (OMCL) stock is 63.1 as of October 26, 2025.
Does Omnicell stock pay dividends?
No, Omnicell (OMCL) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Omnicell dividend payment date?
Omnicell (OMCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Omnicell?
Omnicell (OMCL) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.